Prevalence of helminth infections.

<p>The prevalence of helminth infections is displayed for all infections together, as well as the subgroups intestinal helminth infections and filariases, and for each individual infection.</p

Effect of exposure to ART or CTX-P on helminth infection prevalence.

<p>Effect of exposure to ART or CTX-P on helminth infection prevalence.</p

Study flow.

<p>Study flow displaying the inclusion of study participants. Patients were included in the main analysis if they provided at least 2 stool and urine samples and one blood sample. Patients were included for subanalyses if they provided at least 2 stool samples (intestinal helminths), 2 urine samples (<i>S</i>. <i>haematobium</i>) or 1 blood sample (filariases). </p

Patient characteristics.

<p>Patient characteristics.</p

Participant flow diagram.

<p>Randomisation and flow of participants over a period of 6 months for adults (cohorts 1 to 5), adolescents (cohort 6; 13–17 years), and children (cohort 7; 6–12 years). Similar dose groups are matched with shading (light grey, 3 × 10⁶ PFU; dark grey, 2 × 10⁷ PFU). GP, glycoprotein; ELISA, enzyme-linked immunosorbent assay; PFU, plaque-forming units; rVSV, recombinant vesicular stomatitis virus.</p

Geometric mean titres, seropositivity rates, and proportions of seroresponders to rVSVΔG-ZEBOV-GP measured by ZEBOV PsVNA50 in adults.

<p>Geometric mean titres, seropositivity rates, and proportions of seroresponders to rVSVΔG-ZEBOV-GP measured by ZEBOV PsVNA50 in adults.</p

Geometric mean titres of ZEBOV antibodies in adults by baseline antibody status measured by whole-virion ELISA.

<p>Geometric mean titres of ZEBOV antibodies in adults by baseline antibody status measured by whole-virion ELISA.</p

Description of viraemia by dose and age.

<p>Description of viraemia by dose and age.</p

Geometric mean titres, seropositivity rates, and proportions of seroresponders to rVSVΔG-ZEBOV-GP measured by ZEBOV-GP ELISA in children.

<p>Geometric mean titres, seropositivity rates, and proportions of seroresponders to rVSVΔG-ZEBOV-GP measured by ZEBOV-GP ELISA in children.</p

Baseline characteristics of study participants.

<p>Baseline characteristics of study participants.</p